

Purpose

To describe the requirements and responsibilities for the submission of research projects to Bellberry HRECs for ethical and scientific review, as per chapter 5 of the [National Statement on Ethical Conduct in Human Research \(2025\)](#).

Definitions

Additional Site: Sites other than the lead site involved in a multi-centre study. A separate application is required to be created and submitted in eProtocol for each Principal Investigator at each additional site seeking Bellberry HREC approval.

Clinical Research: research involving human participants for health-related interventions, including drugs, devices, biologicals, surgical techniques, diagnostic and screening tests, therapy, education and care.

CRO: Clinical Research Organisation.

HREC: Human Research Ethics Committee.

Lead Site: The site that submits the initial application in a multi-centre study. This site takes responsibility for responding to the comments from the HREC. It is a decision for the sites and sponsor to determine whether the lead site continues to take responsibility for ongoing submissions (e.g. generic amendments and reports) on behalf of the additional sites.

Multi-Centre Application: The study is conducted at multiple centres and a different Principal Investigator is responsible for each centre. A separate eProtocol application is required from each Principal Investigator.

Multi-Site Application: The study is conducted at multiple sites, and one Principal Investigator has responsibility for the activities at all of the sites. A single application form is required.

Non-clinical Research: Social and behavioural sciences, and non-interventional/non-therapeutic research.

Site Delegate: A representative of the Principal Investigator at the site (e.g., Clinical Research Manager, Study Co-Ordinator, Co-Investigator).

SMO: Site Management Organisation.

Guidance

Initial study submission

The Principal Investigator is responsible for the submission of essential and other study related documents for consideration by the HREC. Investigators are encouraged to refer to BA F1.1.1 Submission Requirements Checklist for a list of documents required to be included in the initial study submission.

Applicants should refer to the following areas for guidance on a specific topic before applying. Some areas of guidance may have templates in their document area. Please see [Bellberry applications](#) for the most up-to-date information.

Public

Submission Requirements and Responsibilities

BA G1	Submission requirements and responsibilities
BA G2	eProtocol Registrations Guidance
BA G3	Protocol Development – Clinical Study
BA G4	Protocol Development - Non-Clinical Study
BA G5	Participant Information & Consent Form development
BA G6	Application Fees
BA G7	Conflict of Interest Guidance
BA G8	CVs & Investigator Qualifications
BA G9	Advertising Guidance
BA G10	Participant Payment & Reimbursement Guidance
BA G11	Researcher Data Storage & Retention Guidance
BA G12	Version Control & Document Naming Conventions
BA G13	Ionising Radiation Guidance
BA G14	Pregnancy and Sexual Health Guidance
BA G15	Insurance and Indemnities Guidance
BA G16	eProtocol Navigation Guide

Document BA F1.1.17 PICF Submission Pathways includes a flowchart for the processing of single site and multi-centre applications. All sites must understand the PICF pathway chosen by the lead site at the initial submission.

Document naming convention requirements can be found in BA G12 Version Control & Document Naming Conventions.

Bellberry's general information regarding consent, including participant information and consent form development, eConsent and translation requirements can be found in BA G5 Participant Information & Consent Form development.

A full and complete research application submitted via eProtocol will be allocated to the next available agenda, generally 10 working days prior to the HREC meeting. If the initial submission is incomplete the HREC's review of the study will be delayed. In this instance, the application will be returned to the Principal Investigator with notes outlining the additional action required prior to resubmission.

The Principal Investigator will receive email notification when a study is allocated to the meeting agenda. A Principal Investigator can expect to receive comments detailing the HREC's deliberations 2 business days following the HREC meeting. Comments are provided via eProtocol.

Multi-Centre Applications

An application is required to be submitted to the Bellberry HREC by the lead/initial site and by each additional/subsequent site via eProtocol.

However, if the initial submission is from a public health site, the submission may be made through the State-based submission platform. In these circumstances all post-initial submission amendments and notifications can also be made via this platform. In this context, please interpret any reference to eProtocol to relate to the applicable submission platform for the project application. The initial site submits all documents to be reviewed by the HREC. Subsequent sites submit the application form and are required to attach relevant documentation to page 7 in accordance with BA F1.1.1 Submission Requirements Checklist. The additional site is required to

use the same document naming convention as used by the lead site (see BA G12 Version Control & Document Naming Conventions).

Studies submitted by a SMO

Organisations may submit an application on behalf of another site where they are not directly conducting the research themselves.

Key Requirements:

- **Authorisation:** The submitting site must have documented authorisation from the site conducting the research, confirming their role in submitting the application and their access to eProtocol.
- **Site-Specific Information:** The application must clearly indicate which site is conducting the research and provide all necessary site details, including Principal Investigator information.
- **Communication & Responsibilities:** The submitting site remains responsible for ensuring that the site conducting the research has reviewed and approved all submitted materials. Any correspondence from the HREC should be communicated promptly to the research site. Additionally, the Site Management Organisation and the site must have a clear communication plan in place to ensure there is no confusion between study management, study facilitation, and HREC requirements. This includes clearly defining roles and responsibilities, ensuring timely information sharing, and maintaining consistency in responses to HREC queries.

Study decision

All submissions will receive notification of the HREC's decision via eProtocol (approval, conditional approval or non-approval), including all submissions under a multi-centre application. If the application is not approved by the HREC, each application will be closed following notification.

Further information or amendments to the submitted documents may be requested by the HREC following its review. Responses to the HREC's initial comments must be provided in eProtocol within 6 months and responses to subsequent comment cycles within 3 months. If a response is unable to be provided within these timeframes, an extension must be requested via email. The HREC will determine whether an extension can be granted.

If a substantial period has passed since the initial review, the application may be required to undergo re-review at a future HREC meeting. Application fees will apply (see BA G6 Application Fees).

If the researcher does not respond and does not request an extension—either via email or within eProtocol—Bellberry will administratively close the application. Closed applications cannot be reactivated. If the study is to proceed, a new application will need to be submitted, and new application fees will apply (see BA G6 Application Fees).

Before initiating research, the investigator/institution is required to have written and dated approval from the HREC for the study protocol, Investigator's Brochure (where applicable to the study), written informed consent form, consent form updates, recruitment procedures (e.g. advertisements), and any other written information to be provided to participants. The Principal Investigator is responsible for ensuring compliance with any site-based governance requirements.

The period of approval is outlined on the HREC approval letter. Approval extends until midnight on the date listed.

Approved study submission

Each site is responsible for site-specific submissions (if applicable). These submissions will include safety notifications and protocol violations related to the site, annual progress reports, and the final report.

During the study, any approved site can submit generic documents on behalf of the other site(s). This may include for example, amendments to the protocol, Investigator's Brochure, questionnaires, the master PICF, annual safety reports, and so on. When an approved site submits on behalf of another site, the Principal Investigator and address of the additional site is to be included. The HREC recommends amendments to essential documents (such as the master PICF, protocol or Investigator's Brochure) be submitted on behalf of all sites. In instances where this does not occur, the submitting site should explain why.

It is the responsibility of the sites and sponsor to determine who will act as the lead site (if required) and to determine site responsibilities for ongoing amendments and reports.

Applicants are encouraged to refer to monitoring approved research (MAR) guidance (and associated documents) for approved study submission requirements.

Most submissions for approved research are reviewed out of session and do not require full HREC review. The review time is dependent on the complexity of the submission.

Studies under CTN

The HREC reviews the scientific validity of the study design, the balance of risk versus harm of the therapeutic good, the ethical acceptability of the study process, and approves the study protocol. The HREC is also responsible for monitoring the conduct of the study.

The institution or organisation at which the study will be conducted, referred to as the 'Approving Authority', gives the final approval for the conduct of the study at the site, having due regard to advice from the HREC.

It is the responsibility of the sponsor to ensure that all relevant approvals are in place before supplying the 'unapproved' therapeutic goods in the clinical study.

Studies under CTA (formerly known as the CTX scheme)

A sponsor applies to the TGA seeking approval to supply 'unapproved' therapeutic goods in a clinical study. The TGA evaluate summary information about the product including relevant, but limited, scientific data (which may be preclinical and early clinical data) prior to the start of a study.

After the TGA have completed their evaluation, the study must then be reviewed by a HREC. The outcome of the TGA's review must be provided in the HREC application. The HREC is responsible for considering the scientific and ethical issues of the proposed study protocol.

Where a study is submitted under the CTN scheme, the HREC may decide that an application must go through the CTA scheme.

Bellberry HREC Contact Officer (*person who will receive correspondence for the HREC about this CTN, if required*):

Name: Jerneen Williams

Position: Director of Operations, Bellberry Ltd

Contact Number: 08 8361 3222

Contact Email: bellberry@bellberry.com.au

Staff Listings in eProtocol

Any individual requiring access to an eProtocol application or notifications may be registered and listed in the personnel information page of the eProtocol application. A study application should have at least one nominated contact listed in addition to the Principal Investigator, for administrative and safety purposes. For further information, please see BA G2 Registrations.

Sponsors, CROs and SMOs are permitted to access applications in eProtocol. Once decided between the sponsor, CRO, SMO and site, a request for eProtocol access occurs through submission of the Organisational Verification of Personnel form (appended to BA G2 eProtocol Registration Guidance document) and by following the registration steps in the eProtocol Registration Guidance document. Once the representative is registered on eProtocol, the Principal Investigator at the site is responsible for adding the representative to the relevant application(s). After the representative has access to the study in eProtocol, they can assist in all areas of the research application for the life of the study, including uploading documentation.

Importantly, only the Principal Investigator or their site delegate can use the 'submit' function in eProtocol, as it is the Principal Investigator that holds ultimate responsibility for the conduct of the research at the site. The declaration for all submissions within eProtocol acknowledges the responsibilities of the Principal Investigator. The Principal Investigator may also choose to remove personnel from their application at any time. For submissions made via alternative platforms please refer to the platform guidance.

Communication between Bellberry and Researchers/Sponsors

Bellberry encourages open and informal communication with researchers/sponsors.

Bellberry staff are committed to providing a professional, high quality and efficient service to the research community and are readily accessible to assist researchers/sponsors through the review process daily.

Communication between Bellberry administration and individuals from the site or sponsor who are not registered and listed on the Personnel Information page of the application will be restricted to matters of an administrative nature e.g. general policy or procedure questions. Any other communication from the Sponsor should be submitted via the Principal Investigator through eProtocol. Bellberry staff can assist Investigators with minor scientific or ethical matters (i.e., clarification of a HREC question). All other matters will be referred to the HREC for consideration and be resolved between the HREC and the Investigator.

Administrative adjustments

Occasionally, Bellberry administration will make minor adjustments to an eProtocol application. These changes might involve correcting study titles or removing contacts as notified through an amendment process.

References

[National Statement on Ethical Conduct in Human Research \(2025\)](#)
[Research Governance Handbook](#)

BA F1.1.1 Submission Requirements Checklist

BA F1.1.5 eProtocol Application Content

BA G2 eProtocol Registrations Guidance

BA G5 Participant Information & Consent Form development

BA G12 Version Control & Document Naming Conventions